Patents by Inventor Steven L. Gallion

Steven L. Gallion has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Certain substituted amides, method of making, and method of use thereof
    Patent number: 7947835
    Abstract: At least one chemical entity chosen from compounds of Formula 2 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein. Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.
    Type: Grant
    Filed: March 9, 2006
    Date of Patent: May 24, 2011
    Assignee: CGI Pharmaceuticals, Inc.
    Inventors: David R. Brittelli, Kevin S. Currie, James W. Darrow, Jeffrey E. Kropf, Seung H. Lee, Steven L. Gallion, Scott A. Mitchell, Douglas A. I. Pippin, Peter A. Blomgren, Douglas Gregory Stafford
  • Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
    Publication number: 20100160292
    Abstract: Methods of inhibiting BTK activity by inhibiting phosphorylation of Y551 of BTK, methods of treating patients by inhibiting BTK activity by inhibiting phosphorylation of Y551 of BTK, chemical entities that bind to BTK and inhibited complexes are provided.
    Type: Application
    Filed: September 11, 2007
    Publication date: June 24, 2010
    Applicant: CGI PHARMACEUTICALS, INC
    Inventors: James A. Whitney, Julie Di Paolo, Mark Velleca, David R. Brittelli, Kevin S. Currie, James W. Darrow, Jeffrey E. Krope, Seung H. Lee, Steven L. Gallion, Scott A. Mitchell, Doughlas A.I. Pippen, Peter A. Blomgren, Doughlas Gregory Stafford
  • Elastase inhibitors
    Patent number: 6693072
    Abstract: This invention relates to compounds which are inhibitors of elastase, particularly human neutrophil elastase. The inhibitors are short, synthetic peptides in which the P2 moiety is substituted with various nitrogen-containing heterocyclic groups. As inhibitors of human neutrophil elastase, the compounds are useful in the treatment of a patient afflicted with a neutrophil associated inflammatory disease.
    Type: Grant
    Filed: December 20, 2000
    Date of Patent: February 17, 2004
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Steven L. Gallion, William A. Metz Jr., Joseph P. Burkhart, Michael R. Angelastro, Norton P. Peet
  • Novel elastase inhibitors
    Publication number: 20030096759
    Abstract: This invention relates to compounds which are inhibitors of elastase, particularly human neutrophil elastase. The inhibitors are short, synthetic peptides in which the P2 moiety is substituted with various nitrogen-containing heterocyclic groups. As inhibitors of human neutrophil elastase, the compounds are useful in the treatment of a patient afflicted with a neutrophil associated inflammatory disease.
    Type: Application
    Filed: December 20, 2000
    Publication date: May 22, 2003
    Inventors: Steven L. Gallion, William A. Metz, Joseph P. Burkhart, Michael R. Angelastro, Norton P. Peet